KZIA Company Profile and Key Details

Q: Who are the executives of KZIA?

Dr. John E. Friend II, M.D.Chief Executive OfficerDr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA,Chief Executive Officer, MD & Executive DirectorDr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBAChief Executive Officer, MD & Executive DirectorMs. Karen R. KrumeichChief Financial OfficerMs. Anna SandhamCompany Sec.Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (Chief Executive Officer, MD & Executive DirectorMs. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICDCompany Sec.

NASDAQ : KZIA

Kazia Therapeutics ADR

$13.59

0.03+0.22%

At Close 4:00 PM

66.24

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Kazia Therapeutics Ltd ADR (KZIA) stock surged +0.22%, trading at $13.59 on NASDAQ, up from the previous close of $13.56. The stock opened at $13.48, fluctuating between $12.75 and $13.93 in the recent session.

Stock Snapshot

13.56

Prev. Close

22.01M

Market Cap

12.75

Day Low

-2.85

P/E Ratio

-4.76255

EPS (TTM)

-0.53

Cash Flow per Share

13.48

Open

1.62M

Number of Shares

13.93

Day High

62.16%

Free Float in %

0.22

Book Value

121.89K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	13.64	13.93	12.75	13.59	122.26K
Jul 10, 2026	12.91	13.65	11.90	13.56	240.56K
Jul 09, 2026	12.51	13.61	12.51	12.98	235.73K
Jul 08, 2026	12.94	13.23	12.25	12.46	285.27K
Jul 07, 2026	12.88	13.31	12.47	13.10	281.99K
Jul 06, 2026	13.24	13.61	12.95	13.08	52.63K
Jul 02, 2026	13.63	14.15	13.14	13.25	116.1K
Jul 01, 2026	14.78	14.81	13.39	13.39	135.62K
Jun 30, 2026	14.40	14.58	14.05	14.08	127.72K
Jun 29, 2026	14.30	15.31	14.07	14.46	195.25K
Jun 26, 2026	13.67	14.61	13.67	14.22	90.09K
Jun 25, 2026	14.65	15.09	13.72	13.92	146.84K
Jun 24, 2026	14.70	15.25	14.40	14.63	206.26K
Jun 23, 2026	13.83	15.07	13.83	14.69	168.24K
Jun 22, 2026	13.91	14.28	13.50	14.00	80.78K
Jun 18, 2026	14.44	14.87	13.32	13.86	195.96K
Jun 17, 2026	13.70	14.78	13.50	14.25	196.32K
Jun 16, 2026	14.13	14.33	13.77	13.77	178.86K
Jun 15, 2026	14.56	14.97	13.67	14.08	146.78K
Jun 12, 2026	12.63	14.41	12.60	14.28	167.24K

Contact Details

Sydney, NSW 2000

Australia

https://www.kaziatherapeutics.com 130 078 7272

About Company

Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Company Overview

Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) closed at $13.59 USD, gaining $0.03 (0.22%) from the previous close of $13.56. The stock is currently mid-range between its 52-week high and low $4.86 and $17.40. With a market capitalization of about $22.01 million, Kazia Therapeutics Ltd ADR is classified as a micro-cap and shows higher-than-market volatility (beta ~2.15). Key stats such as the average daily volume over the past year has been around 229.34 thousand shares, volume is running light vs its 52-week average. Headquartered in Sydney, NSW, Kazia Therapeutics Ltd ADR operates in the Healthcare sector and the Biotechnology industry. Led by CEO John Friend, the company employs approximately 6 people and listed since January 06, 1999. Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel.

Technical Performance

KZIA has shown mixed momentum, gaining 9.32% over the past week and 0.57% over the past quarter, though year-to-date performance is up 2.18%. Short-term trend indicators are bullishly aligned (SMA20 46.74%, SMA50 28.13%, SMA200 17.34%). The stock’s 14-day RSI is 69.24 (firm momentum), while the ATR of 0.87 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -49.14% below its high and over 209.44% above its low. Average 10-day trading volume of 203.07 thousand shares is in line with the 3-month average of 217.99 thousand, indicating normal recent market interest.

Valuation Metrics

Kazia Therapeutics Ltd ADR trades at a P/E ratio of -1.86, slightly below the S&P 500 average, with a price-to-sales ratio of 1584.37 and a price-to-book ratio of 1.3 suggesting the stock is closer to book value. The P/FCF stands at -3.44, also below market averages.

Dividend & Fair Value

Kazia Therapeutics Ltd ADR last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.48. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Kazia Therapeutics Ltd ADR generated EPS of -$12.31 over the past year. Five-year average earnings growth is 25.92%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $34.00 to $18.00. The high target offers 150.18% upside. The low target suggests 32.45% downside. The mean target is $23.00. This offers 69.24% upside. Kazia Therapeutics Ltd ADR earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 16, 2026, missed forecasts by 5760.55%. The prior quarter beat by 6529.86%. Over the last six quarters, Apple has recorded several small beats. These include 108.12% in November 19, 2024.

Shareholding & Insider Activity

Kazia Therapeutics Ltd ADR has 1.36 million shares outstanding. The public float is 422.58 million shares, elevated short interest at 2.83% of float. This equals 31.07 thousand shares. The short ratio is 0.05 days. Institutional investors hold 9.73% of the float. Insiders own 8.48%.

Financial & Profitability Overview

Over the trailing twelve months, Kazia Therapeutics ADR generated $42.00K in revenue, or $0.04 per share. Gross margin was 100.00%, operating margin -33850.00%, and net profit margin -49290.48%. Returns are negative, with ROA at -341.56% and ROE at 249.39%.
On valuation metrics, Kazia Therapeutics ADR trades at a P/E of -1.86, P/S of 1584.37 and P/B of 1.30. The current ratio is 2.87 and quick ratio is 2.87. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is 5837.50 days. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -133.90.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2025, Kazia Therapeutics ADR posted revenue of $42.00K, down slightly from $2.31M in the prior quarter. Gross profit was $42.00K (margin 100.00%). Operating income was - $14.22M (margin -33850.0%). Net income was- $20.70M (EPS - $18.90).
The company ended the quarter with $4.35M in cash and short-term investments, a total debt of $396.00K, and net debt of - $3.95M. Total assets were $6.06M, with equity of - $8.30M. Financials further reflected weakness, with operating cash flow of - $13.28M, free cash flow of - $13.28M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Kazia Therapeutics Ltd ADR stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 2.43%, with price expected at $13.92 by July 27, 2026, within a range of $12.72 to $15.12 3-Month Outlook: Projected fall of -61.59%, reaching $5.22 by October 08, 2026, with a range of $3.62 to $6.38. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by July 13, 2027, within a range of $0.00 to $5.53.

Key Takeaways

Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) shares are flat 2.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Kazia Therapeutics Ltd ADR trading at a premium to the broader market with a P/E of -1.86. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.42, suggesting 13.47% upside. Our AI forecast model points to short-term strength (2.43% over two weeks), a medium-term fall (-61.59% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Kazia Therapeutics Ltd ADR (KZIA) stock price?

Kazia Therapeutics Ltd ADR (NASDAQ: KZIA) stock price is $13.59 in the last trading session. During the trading session, KZIA stock reached the peak price of $13.93 while $12.75 was the lowest point it dropped to. The percentage change in KZIA stock occurred in the recent session was 0.22% while the dollar amount for the price change in KZIA stock was $0.03.

KZIA's industry and sector of operation?

The NASDAQ listed KZIA is part of Biotechnology industry that operates in the broader Healthcare sector. Kazia Therapeutics Ltd ADR designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of KZIA?

Dr. John E. Friend II, M.D.
Chief Executive Officer
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA,
Chief Executive Officer, MD & Executive Director
Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Chief Executive Officer, MD & Executive Director
Ms. Karen R. Krumeich
Chief Financial Officer
Ms. Anna Sandham
Company Sec.
Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (
Chief Executive Officer, MD & Executive Director
Ms. Catherine Jane Hill ACA, B.Sc., BSc (Hons), C.A., GAICD
Company Sec.

How KZIA did perform over past 52-week?

KZIA's closing price is 179.63% higher than its 52-week low of $4.86 where as its distance from 52-week high of $17.40 is -21.9%.

How many employees does KZIA have?

Number of KZIA employees currently stands at 6.

Link for KZIA official website?

Official Website of KZIA is: https://www.kaziatherapeutics.com

How do I contact KZIA?

KZIA could be contacted at phone 130 078 7272 and can also be accessed through its website. KZIA operates from Three International Towers, Sydney, NSW 2000, Australia.

How many shares of KZIA are traded daily?

KZIA stock volume for the day was 121.89K shares. The average number of KZIA shares traded daily for last 3 months was 229.34K.

What is the market cap of KZIA currently?

The market value of KZIA currently stands at $22.01M with its latest stock price at $13.59 and 1.62M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	6
Beta	2.15
Sales or Revenue	$42.00K
5Y Sales Change%	-0.988%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

KZIA Company Profile and Key Details

Kazia Therapeutics ADR

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Company Overview

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways